lead-optimization
(2)
The Company That Turned "Prove It" Into a Business
For 20 years, ActiveProspect has sold one unglamorous promise to marketers: keep the receipt. In a regulatory minefield where a single unwanted robocall can cost $500 to $1,500, that receipt is the whole business.
MOMA Therapeutics
MOMA Therapeutics is a Cambridge, Massachusetts biotech building precision small-molecule medicines against 'molecular machines' - the highly dynamic, shape-shifting enzymes (ATPases, GTPases and related proteins) that power cellular processes and underlie cancer and other diseases. Spun out of Third Rock Ventures in 2020 by four academic leaders in protein biophysics and structural biology, MOMA's proprietary KNOMATIC platform fuses deep structural insight, advanced hit-finding (fragment and DNA-encoded library screening) and machine-learning-driven lead optimization to drug targets long considered intractable. The company has raised about $236M, advanced its first oncology program into the clinic, and partnered with Roche and Bayer.